Champions Oncology, Inc.
CSBR · NASDAQ
10/31/2025 | 7/31/2025 | 4/30/2025 | 1/31/2025 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 7.4% | 13.3% | -27.5% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 49.3% | 40.3% | 38% | 58.8% |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $0 | $0 | $0 | $0 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Income | $0 | -$0 | -$0 | $0 |
| % Margin | 1.2% | -3.6% | -13.9% | 26.4% |
| Other Income/Exp. Net | $0 | $0 | -$0 | $0 |
| Pre-Tax Income | $0 | -$0 | -$0 | $0 |
| Tax Expense | $0 | $0 | -$0 | $0 |
| Net Income | $0 | -$0 | -$0 | $0 |
| % Margin | 2% | -3.1% | -14.8% | 26.4% |
| EPS | 0.019 | -0.032 | -0.13 | 0.33 |
| % Growth | 161.4% | 75.7% | -139.4% | – |
| EPS Diluted | 0.019 | -0.032 | -0.13 | 0.31 |
| Weighted Avg Shares Out | 0 | 0 | 0 | 0 |
| Weighted Avg Shares Out Dil | 0 | 0 | 0 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | $0 | -$0 | -$0 | $0 |
| % Margin | 4.1% | -0.7% | -12.7% | 28.9% |